Appendix I: PrEP search strategy for a two-step process

Step 1: Building a search strategy for the PRS Database:

* Search Development: 24 Citations used to develop the search
	1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV*, et al.* Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med* 2012,4:151ra125.
	2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J*, et al.* Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med* 2012,367:399-410.
	3. Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Wooley SB*, et al.* Two years of Truvada for pre-exposure prophylaxis utilization in the US. *J Int AIDS Soc* 2014,17:19730.
	4. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. *J Acquir Immune Defic Syndr* 2010,54:548-555.
	5. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. *Clin Infect Dis* 2010,50 Suppl 3:S96-101.
	6. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M*, et al.* Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis* 2014,14:820-829.
	7. Grant RM, Buchbinder S, Cates W, Jr., Clarke E, Coates T, Cohen MS*, et al.* AIDS. Promote HIV chemoprophylaxis research, don't prevent it. *Science* 2005,309:2170-2171.
	8. Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G. Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014. *Clin Infect Dis* 2016,63:672-677.
	9. Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K*, et al.* The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. *J Acquir Immune Defic Syndr* 2013,62:447-456.
	10. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. *J Acquir Immune Defic Syndr* 2006,43:376-377.
	11. Khanna AS, Michaels S, Skaathun B, Morgan E, Green K, Young L*, et al.* Preexposure Prophylaxis Awareness and Use in a Population-Based Sample of Young Black Men Who Have Sex With Men. *JAMA Intern Med* 2016,176:136-138.
	12. Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. *AIDS Patient Care STDS* 2012,26:222-233.
	13. Kuo I, Olsen H, Patrick R, Phillips G, 2nd, Magnus M, Opoku J*, et al.* Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. *Drug Alcohol Depend* 2016,164:8-13.
	14. Kwakwa HA, Bessias S, Sturgis D, Mvula N, Wahome R, Coyle C*, et al.* Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population. *AIDS Behav* 2016,20:1443-1450.
	15. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M*, et al.* Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. *J Acquir Immune Defic Syndr* 2014,67:528-537.
	16. Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L*, et al.* Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. *J Acquir Immune Defic Syndr* 2013,64:87-94.
	17. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR*, et al.* No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. *PLoS One* 2013,8:e81997.
	18. Psaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD*, et al.* An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. *J Acquir Immune Defic Syndr* 2014,66:522-529.
	19. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). *AIDS Educ Prev* 2012,24:408-421.
	20. Snowden JM, Chen YH, McFarland W, Raymond HF. Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities. *Sex Transm Infect* 2017,93:52-55.
	21. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. *Curr HIV/AIDS Rep* 2008,5:186-192.
	22. Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T*, et al.* Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. *AIDS Care* 2013,25:961-967.
	23. Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. *AIDS Patient Care STDS* 2011,25:365-370.
	24. Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013. *PLoS One* 2015,10:e0128971.
* Databases Searched (platform): Search years 2000 – 2017 run in the databases April 2018
	1. MEDLINE (OVID)\*
	2. EMBASE (OVID)
	3. PsycINFO (OVID)
	4. CINAHL (EBSCOhost)

\*Full electronic search strategy for MEDLINE, including any limits used, provided below. Please contact the corresponding author for the searches of EMBASE, PsycINFO and CINAHL.

**MEDLINE (OVID) PrEP Search strategy**

Symbol Key

/ = MeSH term

ti = title ab = abstract

$ = truncation

**HIV or AIDS or STD MeSH and keywords**

1. HIV infections/
2. AIDS/
3. Sexually Transmitted Diseases/
4. HIV seropositivity/
5. HIV seronegativity/
6. AIDS serodiagnosis/
7. Hepatitis C/
8. HIV.ti,ab
9. (AIDS not hearing).ti,ab
10. Hepatitis C.ti,ab
11. HCV.ti,ab
12. Sexually transmitted disease$.ti,ab
13. Sexually transmitted infection$.ti,ab
14. (STD or STDs or STI or STIs).ti,ab
15. or/1-14

**Pre Exposure Prophylaxis MeSH and Keywords**

1. Pre-Exposure Prophylaxis/
2. Chemoprevention/
3. Pre exposure prophylaxis.ti,ab
4. Preexposure prophylaxis.ti,ab
5. PrEP.ti,ab
6. (Chemoprophylaxis or Chemo prophylaxis or chemoprevention).ti,ab
7. or/16-21
8. 15 and 22
* Manual Search:
	1. Hand Search 52 Journals (Quarterly) January 2017 – December 2017
	2. Check reference list of included citations (ongoing)
	3. PubMed ad hoc keyword searches (ongoing)
	4. Table of contents alerts from journals (ongoing)

Step 2: Query of the PRS Database

* Query of the PRS Database: Last run April 2018
	+ Years searched = 2000 to 2017
	+ Citations previously tagged by PRS coders as the following
		- ( ( [Specify HIV/AIDS/STD/HBV/HCV prevention focus} = ( [PrEP/PEP] OR [PrEP] ) OR [Keywords= [PrEPCQ] ) ) AND [Specify HIV/AIDS/STD/HBV/HCV prevention focus} NOT [Policy / Commentary / Advocacy (non-behavioral)])

Appendix II: Supplemental Tables and Figures

Supplemental Table 1: Included studies' populations, proportions, and quality scores by study years (N=95)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** **yeara** | **First author, publication year** | **Key Populations** | **Sample size** | **Number of PrEP users** | **Proportion (%)** | **Recall periodb** | **Target population** | **Quality scorec** |
| MSM | Black | Hispanic/Latino | PWID | Youth | So | TGW |
| MSM only or focused (n=78) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 2004 | Chen, 20161 d | √ |  |  |  |  |  |  | 1,211 | 0 | 0.0 | 12 mo | MSM [NHBS] | 3 |
|  |  | √ |  |  |  |  |  | 77 | 0 | 0 |  |  |  |
|  |  |  | √ |  |  |  |  | 227 | 0 | 0 |  |  |  |
|  |  |  |  |  | √ |  |  | 151 | 0 | 0 |  |  |  |
| 2004 | Kellerman, 20062 | (√) |  |  |  |  |  |  | 1,041 | 50 | 4.8 | Ever | Minority Gay Pride attendees | 3 |
|  |  |  |  |  |  |  | √ |  | 88 | 6 | 6.8 |  |  |  |
| 2005 | Voetsch, 20073 | (√) |  |  |  |  |  |  | 397 | 1 | 0.3 | Ever | Latinx or non-white men who attended Minority Gay Pride | 3 |
| 2006 | Koblin, 20114 | √ |  |  |  | ` |  |  | 645 | 15 | 2.3 | Ever | Substance using MSM | 3 |
| 2007 | Mansergh, 20105 | √ |  |  |  |  |  |  | 454 | 9 | 2.0 | 6 mo | MSM | 3 |
| 2008 | Chen, 20161 d | √ |  |  |  |  |  |  | 407 | 0 | 0.0 | --- | --- | --- |
|  |  | √ |  |  |  |  |  | 27 | 0 | 0 |  |  |  |
|  |  |  | √ |  |  |  |  | 96 | 0 | 0 |  |  |  |
|  |  |  |  |  | √ |  |  | 62 | 0 | 0 |  |  |  |
| 2008 | Golub, 20106 | √ |  |  |  |  |  |  | 180 | 3 | 1.7 | Ever | MSM | 3 |
| 2009 | Barash, 20107 | √ |  |  |  |  |  |  | 215 | 5 | 2.3 | Ever | MSM  | 4 |
| 2010 | Hood, 20168 | √ |  |  |  |  |  |  | 681 | 5 | 0.7 | Ever | MSM | 2 |
| 2010 | Krakower, 20129 | √ |  |  |  |  |  |  | 289 | 2 | 0.7 | Ever | MSM | 3 |
| 2011 | Chen, 20161 d | √ |  |  |  |  |  |  | 371 | 0 | 0.0 | --- | --- | --- |
|  |  | √ |  |  |  |  |  | 23 | 0 | 0 |  |  |  |
|  |  |  | √ |  |  |  |  | 75 | 0 | 0 |  |  |  |
|  |  |  |  |  | √ |  |  | 60 | 0 | 0 |  |  |  |
| 2011 | Dolezal, 201510 | √ |  |  |  |  |  |  | 228 | 0 | 0 | Ever | MSM (18-30 years old) | 4 |
|  |  | √ |  |  |  |  |  | 21 | 0 | 0 |  |  |  |
|  |  |  | √ |  |  |  |  | 100 | 0 | 0 |  |  |  |
| 2011 | Fallon, 201711 | √ |  |  |  |  | √ |  | 399 | 0 | 0.0 | 12 mo | MSM [NHBS] | 4 |
|  |  | √ |  |  |  |  | 301 | 0 | 0 |  |  |  |
|  |  |  | √ |  |  |  | 9 | 0 | 0 |  |  |  |
|  |  |  |  | √ |  |  | 12 | 0 | 0 |  |  |  |
|  |  |  |  |  | √ |  | 137 | 0 | 0 |  |  |  |
| 2011 | Krakower, 20129 | √ |  |  |  |  |  |  | 3,385 | 29 | 0.9 | --- | --- | --- |
| 2011 | Patrick, 201712 | √ |  |  |  |  | √ |  | 602 | 1 | 0.2 | 12 mo | MSM [NHBS] | 3 |
| 2011 | Rucinski, 201313 | √ |  |  |  |  |  |  | 329 | 2 | 0.6 | 6 mo | MSM (18-40) | 3 |
|  |  | √ |  |  |  |  |  | 60 | 0 | 0 |  |  |
|  |  |  | √ |  |  |  |  | 49 | 0 | 0 |  |  |  |
| 2011 | Saberi, 201214 | √ |  |  |  |  |  |  | 212 | 10 | 4.7 | Ever | MSM | 4 |
| 2012 | Bauermeister, 201315 | √ |  |  |  | √ |  |  | 1,507 | 11 | 0.7 | Ever | Youth (18-24) MSM | 4 |
| 2012 | Brooks, 201516 | √ | √ |  |  |  |  |  | 224 | 0 | 0 | Ever | Low socioeconomic status black MSM | 4 |
| 2012 | Hoff, 201517 | √ |  |  |  |  |  |  | 340 | 33 | 9.6 | Ever | MSM HIV-serodiscordant/HIV-concordant couple | 4 |
| 2012 | Mimiaga, 201418 | √ |  |  |  |  |  |  | 40 | 4 | 10.0 | Ever | Substance using MSM | 3 |
| 2013 | Chan, 201519 | √ |  |  |  |  |  |  | 538 | 10 | 1.9 | Ever | MSM | 2 |
| 2013 | Cohen, 201520 | √ |  |  |  |  |  |  | 557 | 17 | 3.1 | Ever | MSM/TGW | 3 |
| 2013 | Eaton, 201521 | √ | √ |  |  |  | √ |  | 436 | 6 | 1.4 | Ever | Black MSM | 4 |
| 2013 | Garnett, 201822  | √ | √ |  |  |  |  |  | 1,739 | 33 | 1.9 | Ever | Black substance using MSM/TGW | 4 |
| 2013 | Giguere, 201623 | √ |  |  |  |  |  |  | 12 | 0 | 0 | Ever | Young (18-30) MSM/TGW sex workers | 2 |
|  |  |  |  |  |  |  |  | √ | 8 | 0 | 0 |  |  |
| 2013 | Golub, 201724 | √ |  |  |  |  |  |  | 160 | 5 | 3.1 | Current | MSM | 3 |
| 2013 | Gupta, 201725 | √ |  |  |  |  |  |  | 270 | 6 | 2.2 | Ever | MSM | 4 |
| 2013 | Khanna, 201626 | √ | √ |  |  |  |  |  | 266 | 10 | 3.8 | Ever | Young (16-29) black MSM | 3 |
| 2013 | Lancki, 201827 e | √ | √ |  |  |  |  |  | 300 | 12 | 4.0 | Ever | Young (16-29) black MSM | 4 |
| 2013 | Mayer, 201628 | √ |  |  |  |  |  |  | 4,043 | 61 | 1.5 | Ever | MSM | 4 |
| 2013 | Oldenburg, 201629 | √ |  |  |  |  |  |  | 254 | 13 | 5.1 | Ever | Substance using MSM | 4 |
| 2013 | Raifman, 201830 g | √ | √ |  |  |  |  |  | 34 | 0 | 0 | Ever | MSM | 2 |
|  |  | √ |  |  |  |  | 50 | 2 | 4.0 |  |  |  |
|  |  |  |  | √ |  |  | 101 | 0 | 0 |  |  |  |
| 2014 | Adams, 201631 f | √ |  |  |  |  |  |  | 537 | 35 | 6.5 | 12 mo | MSM [NHBS] | 3 |
| 2014 | Eaton, 201732 | √ | √ |  |  |  |  |  | 1,274 | 58 | 4.6 | Current | Black MSM/TGW | 4 |
|  |  |  |  |  | √ |  | 923 | 52 | 5.6 |  |  |  |
| 2014 | Hoots, 201633 | √ |  |  |  |  |  |  | 6,483 | 237 | 3.7 | 12 mo | MSM [NHBS] | 3 |
|  |  | √ |  |  |  |  |  | 1,458 | 36 | 2.5 |  |  |  |
|  |  |  | √ |  |  |  |  | 1,812 | 47 | 2.6 |  |  |  |
|  |  |  |  |  | √ |  |  | 1,492 | 40 | 2.7 |  |  |  |
| 2014 | Khanna, 201626 | √ | √ |  |  |  |  |  | 622 | 22 | 3.5 | --- | --- | --- |
| 2014 | Klevens, 201834 f | √ | √ |  |  |  |  |  | 33 | 4 | 12.1 | 12 mo | MSM [NHBS] | 2 |
|  |  |  | √ |  |  |  |  | 54 | 0 | 0 |  |  |  |
|  |  |  |  |  | √ |  |  | 52 | 1 | 1.9 |  |  |  |
| 2014 | Kurtz, 201635 | √ |  |  |  |  | √ |  | 31 | 1 | 3.2 | Ever | MSM | 2 |
| 2014 | Levy, 2017 36 f | √ |  |  |  |  | √ |  | 314 | 28 | 8.9 | 12 mo | MSM [NHBS] | 4 |
| 2014 | Marks, 201737 | √ |  |  |  | √ |  |  | 2,347 | 80 | 3.4 | Ever | Youth (18-24) MSM | 4 |
|  |  | √ |  |  |  |  | 452 | 12 | 2.7 |  |  |
|  |  |  | √ |  |  |  | 859 | 29 | 3.4 |  |  |  |
|  |  |  |  |  | √ |  | 993 | 39 | 3.9 |  |  |  |
| 2014 | Mayer, 201628 | √ |  |  |  |  |  |  | 2,737 | 62 | 2.3 | --- | --- | --- |
| 2014 | Merchant, 201638 | √ |  |  |  |  |  |  | 184 | 6 | 3.3 | Ever | MSM | 3 |
| 2014 | Parsons, 201639 | √ |  |  |  |  |  |  | 948 | 68 | 7.2 | Ever | MSM, MSM/W | 4 |
|  |  |  |  |  |  |  |  |  |  | 56 | 5.9 | Current |  |  |
| 2014 | Patrick, 201712 f | √ |  |  |  |  | √ |  | 744 | 30 | 4.0 | --- | --- | --- |
| 2014  | Snowden, 201740 f | √ | √ |  |  |  |  |  | 13 | 1 | 7.7 | 12 mo | MSM [NHBS] | 3 |
|  |  | √ |  |  |  |  | 47 | 2 | 4.3 |  |  |  |
|  |  |  |  | √ |  |  | 24 | 0 | 0 |  |  |  |
| 2014 | Strauss, 201741 | √ |  |  |  |  |  |  | 759 | 66 | 8.7 | Ever | MSM | 4 |
|  | √ |  |  |  |  |  | 146 | 15 | 10.3 |  |  |  |
|  |  |  | √ |  |  |  |  | 212 | 12 | 5.7 |  |  |  |
| 2015 | Arrington-Sanders, 201642 | √ | √ |  |  | √ |  |  | 147 | 12 | 8.2 | Current | Youth (15-24) black MSM  | 3 |
| 2015 | Beymer, 201843 | √ |  |  |  |  |  |  | 761 | 74 | 9.7 | Ever | Young (18-29) MSM | 3 |
| 2015 | Eaton, 201744 | √ |  |  |  |  | √ |  | 285 | 21 | 7.4 | Current | Black/White MSM, Black/White TGW | 4 |
| 2015 | Friedman, 201945 | √ | √ |  |  |  |  |  | 2398 | 189 | 7.9 | Current | Black MSM | 4 |
| 2015 | Goedel, 201646 | √ |  |  |  |  | √ |  | 84 | 10 | 11.9 | Current | MSM who use Grindr | 3 |
| 2015 | Grov, 201647 | √ |  |  |  |  |  |  | 2,902 | 461 | 15.9 | Ever | MSM, MSM/W | 3 |
| 2015 | Holloway, 201748 | √ |  |  |  |  |  |  | 761 | 74 | 9.7 | Ever | Young (18-29) MSM | 4 |
|  |  | √ |  |  |  |  |  | 193 | 19 | 9.7 |  |  |
|  |  |  | √ |  |  |  |  | 243 | 16 | 6.6 |  |  |
|  |  |  |  |  | √ |  |  | 470 | 36 | 7.7 |  |  |  |
| 2015 | Jaiswal, 201849 | √ |  |  |  | √ |  |  | 492 | 71 | 14.4 | Ever | Young (22&23) sexual minority men | 4 |
|  |  |  | √ |  |  |  |  |  | 129 | 17 | 13.2 |  |  |
|  |  |  |  | √ |  |  |  |  | 153 | 28 | 18.3 |  |  |
| 2015 | Kahle, 201850 | √ |  |  |  |  |  |  | 524 | 11 | 2.1 | Current  | MSM | 2 |
| 2015 | Kalichman, 201751 | √ |  |  |  |  | √ |  | 272 | 24 | 8.8 | Current | MSM | 2 |
| 2015 | Kuhns, 201752 | √ |  |  |  |  |  |  | 394 | 48 | 12.2 | Ever | Young (18-29) MSM | 4 |
|  |  | √ |  |  |  |  |  | 193 | 9 | 4.9 |  |  |
|  |  |  | √ |  |  |  |  | 77 | 9 | 11.7 |  |  |
|  |  |  |  |  |  | √ |  | 156 | 11 | 7.1 |  |  |  |
| 2015 | Li, 201853 | √ |  |  |  |  |  |  | 4,013 | 301 | 7.5 | 12 mo | MSM (15 and up) | 2 |
|  |  |  | √ |  |  |  |  |  | 147 | 11 | 7.5 |  |  |  |
|  |  |  |  | √ |  |  |  |  | 566 | 43 | 7.6 |  |  |  |
|  |  |  |  |  |  | √ |  |  | 600 | 21 | 3.5 |  |  |  |
| 2015 | Parsons, 201754 | √ |  |  |  |  |  |  | 1,013 | 100 | 9.9 | Ever | MSM, MSM/W | 4 |
|  |  |  |  |  |  |  |  |  |  | 82 | 8.1 | Current |  |  |
| 2015 | Patel, 201855 | √ |  |  |  |  |  |  | 45 | 6 | 13.3 | Current | Black/White MSM | 2 |
| 2015 | Patel, 201856 | √ | √ |  |  |  |  |  | 26 | 4 | 15.4 | Current | Young (18-35) black MSM | 3 |
| 2015 | Pawson, 201857 | √ |  |  |  |  |  |  | 19 | 2 | 10.5 | Current | MSM, MSM/W | 2 |
| 2015 | Whitfield, 201858 | √ |  |  |  |  |  |  | 985 | 203 | 20.6 | Ever | MSM | 3 |
|  |  |  |  |  |  |  |  |  |  | 172 | 17.5 | Current |  |  |
| 2016 | Biello, 201859 | √ |  |  |  |  |  |  | 4,630 | 689 | 14.9 | Ever | MSM, Trans | 2 |
| 2016 | Biello, 201760 | (√) |  |  |  |  |  |  | 36 | 13 | 36.1 | Ever | Young (15-29) MSM or Trans who have sex with men | 3 |
| 2016 | Garcia, 201761 | √ |  | √ |  |  | √ |  | 159 | 64 | 40.3 | Current | Latino MSM | 3 |
| 2016 | Grov, 201862 i | √ |  |  |  |  |  |  | 4,187 | 495 | 11.8 | Current | MSM | 4 |
| 2016 | Hammack, 201863 | √ |  |  |  |  |  |  | 470 | 21 | 4.5 | Current | MSM (18-25, 34-41, and 52-59) | 3 |
| 2016 | Hubach, 201764 | √ |  |  |  |  | √ |  | 20 | 3 | 15.0 | Current | MSM | 3 |
| 2016 | Morgan, 201865 | √ |  |  |  |  |  |  | 885 | 76 | 8.6 | Ever | Young (16-29 ) MSM/TGW | 4 |
|  |  |  | √ |  |  |  |  |  | 19 | 259 | 7.3 |  |  |  |
|  |  |  |  | √ |  |  |  |  | 12 | 273 | 4.4 |  |  |  |
| 2016 | Newcomb, 201866 | √ |  |  |  |  |  |  | 4,002 | 372 | 9.3 | 6 mo | Young (16-29) MSM HIV-seroconcordant couple | 4 |
| 2016 | Okafor, 201767 | √ |  |  |  |  |  |  | 185 | 37 | 20.0 | 6 mo | MSM | 3 |
|  |  | √ |  |  |  |  |  | 75 | 16 | 21.3 |  |  |  |
|  |  |  | √ |  |  |  |  | 76 | 13 | 17.1 |  |  |  |
|  |  |  |  |  | √ |  |  | 48 | 7 | 14.6 |  |  |  |
| 2016 | Phillips, 201968  | √ |  |  |  |  |  |  | 906 | 63 | 7.0 | 6 mo | Young (16-29) MSM/TGW | 4 |
|  |  |  | √ |  |  |  |  |  | 257 | 20 | 7.8 |  |  |
|  |  |  |  | √ |  |  |  |  | 280 | 13 | 4.6 |  |  |  |
|  |  |  |  |  |  |  |  | √ | 42 | 6 | 14.3 |  |  |  |
| 2016 | Rolle, 201769 | √ | √ |  |  |  | √ |  | 192 | 8 | 4.2 | Ever | Young (16-29) black MSM | 3 |
| 2016 | Sang, 201870 | √ | √ |  |  |  |  |  | 772 | 79 | 10.2 | Ever | Black MSM | 4 |
| 2016 | Shover, 201871 | (√) |  |  |  |  |  |  | 19,587 | 2,613 | 13.3 | Ever | Men, TGW/TGM or gender queer person visited a LGBT center | 3 |
|  |  | √ |  |  |  |  |  |  | 18,954 | 1,868 | 9.9 | Current |  |
|  |  | (√) | √ |  |  |  |  |  | 1,375 | 119 | 8.7 |  |  |
|  |  |  |  | √ |  |  |  |  | 6,365 | 410 | 6.4 |  |  |  |
|  |  |  |  |  | √ |  |  |  | 330 | 32 | 9.7 |  |  |  |
|  |  |  |  |  |  | √ |  |  | 189 | 4,182 | 4.5 |  |  |  |
|  |  |  |  |  |  |  |  | √ | 389 | 20 | 5.1 |  |  |  |
| 2016 | Young, 201872 | √ |  |  |  |  |  |  | 406 | 40 | 9.9 | Ever | Young (18-35) non-white MSM | 3 |
| 2017 | Brinkley-Rubinstein, 201873 | √ |  |  |  |  |  |  | 26 | 0 | 0 | Ever | Incarcerated MSM | 2 |
| 2017 | Chen, 201874 h | √ |  |  |  |  |  |  | 392 | 176 | 4439 | 12 mo | MSM [NHBS] | 3 |
| 2017 | Eaton, 201875 | √ | √ |  |  |  |  |  | 498 | 77 | 15.5 | Current | Black MSM/TGW | 4 |
| 2017 | John, 2019\*76 | √ |  |  |  |  |  |  | 3125 | 350 | 11.2 | Current | MSM | 3 |
| 2017 | Meunier, 201777 | √ |  |  |  |  |  |  | 191 | 78 | 40.9 | Ever | MSM, Trans who have sex with men | 3 |
|  |  | √ |  |  |  |  |  | 14 | 3 | 21.4 | Current |  |
|  |  |  | √ |  |  |  |  | 42 | 12 | 28.6 |  |  |
| 2017 | Quinn, 201878 | √ | √ |  |  |  |  |  | 44 | 10 | 22.7 | Ever | Young (16-25) black MSM | 3 |
| Non- or not focusing MSM (n=17) |  |  |  |  |  |  |  |  |  |  |  |  |
| 2012 | Kuo, 201679 |  |  |  | √ |  |  |  | 304 | 0 | 0 | 12 mo | Older PWID [NHBS] | 3 |
|  |  |  | √ |  |  |  |  | 294 | 0 | 0 |  |  |
| 2013 | Kuhns, 201680 |  |  |  |  |  |  | √ | 180 | 9 | 5.0 | Ever | Young (16-29) TGW | 3 |
| 2013 | Rodriguez, 201781 |  |  |  |  |  | √ |  | 12 | 0 | 0 | Ever | HIV-negative Men in HIV-serodiscordant heterosexual couples | 2 |
| 2014 | Calabrese, 201682 |  |  |  |  |  |  |  | 154 | 0 | 0 | Ever | Adults in general  | 3 |
|  |  |  | √ |  |  |  |  |  | 9 | 0 | 0 |  |  |  |
|  |  |  |  | √ |  |  |  |  | 17 | 0 | 0 |  |  |  |
| 2014 | Patel, 201983 |  |  |  |  |  | √ |  | 225 | 1 | 0.4 | Ever | High-risk Women | 4 |
| 2014 | Raifman, 201984 |  |  |  |  |  |  |  | 1431 | 6 | 0.4 | Ever | Women | 2 |
| 2014 | Sevelius, 201685 |  |  |  |  |  |  | √ | 30 | 0 | 0 | Ever | TGW | 3 |
|  |  |  | √ |  |  |  |  | 5 | 0 | 0 |  |  |  |
|  |  |  |  | √ |  |  |  | 6 | 0 | 0 |  |  |  |
| 2014 | Wilson, 201686 |  |  |  |  | √ |  | √ | 67 | 1 | 1.5 | Ever | Youth (16-24) TGW | 1 |
| 2015 | Reisner, 201787 |  |  |  |  | √ |  |  | 121 | 10 | 8.3 | Ever | Youth (16-24) Trans | 2 |
|  |  |  |  |  |  |  | √ | 79 | 10 | 12.7 |  |  |
| 2015 | Schueler, 201988 |  |  |  |  |  |  |  | 218 | 13 | 6.0 | Ever | MSM/Trans and those in their transmission network | 4 |
|  |  | √ |  |  |  |  |  |  | 111 | 10 | 9.1 |  |  |
|  |  |  | √ |  |  |  |  |  | 190 | 11 | 5.8 |  |  |
|  |  |  |  | √ |  |  |  |  | 20 | 1 | 5.0 |  |  |
|  |  |  |  |  |  |  |  | √ | 6 | 0 | 0 |  |  |
| 2015 | Walters, 201789 |  |  |  | √ |  |  |  | 118 | 1 | 0.8 | 12 mo | Women WID [NHBS] | 2 |
| 2016 | Misra, 201790 |  |  |  |  |  |  |  | 621 | 87 | 14.0 | Ever | HIV-serodiscordant couple | 4 |
|  |  | √ |  |  |  |  |  |  | 251 | 27 | 10.7 |  |  |
|  |  |  | √ |  |  |  |  |  | 177 | 22 | 12.4 |  |  |
|  |  |  |  | √ |  |  |  |  | 193 | 30 | 15.5 |  |  |
|  |  |  |  |  | √ |  |  |  | 1 | 0 | 0 |  |  |  |
| 2016 | Rael, 201891 |  |  |  |  |  |  | √ | 27 | 6 | 22.2 | Ever | TGW | 3 |
| 2016 | Shrestha, 201792 |  |  |  |  |  |  |  | 400 | 7 | 1.8 | Ever | Substance users | 3 |
| 2017 | Bazzi, 201893 |  |  |  | √ |  |  |  | 33 | 1 | 3.0 | Ever | PWID | 3 |
| 2017 | Chandran, 201994 |  |  |  |  | √ | √ |  | 168 | 8 | 4.8 | Current | Youth (15-24) men  | 3 |
| 2017 | Willie, 201895 |  |  |  |  |  |  |  | 191 | 5 | 2.4 | Ever | High-risk women (18-35) | 1 |

Black: African American/ black; HIV: Human immunodeficiency virus, LGBT: lesbian, gay, bisexual, and transgender; MSM: men who have sex with men, MSM/W: men who have sex with men and women; NHBS: CDC National HIV Behavioral Surveillance; PWID: persons who inject drugs; So: people in the Southern United States; TGM: transgender men; TGW: transgender women; Trans: transgender persons; WID: who inject drugs; Youth: youth aged 13 to 24 years old

 \*Online publication year. Study was available electronically before it was published in print.

aMidpoint of study years if the study were conducted over multiple years.

bDuration of recall period for PrEP use: ever used, current use, or have used in the last 6 or 12 months.

cRisk of bias was assessed by using the Modified Newcastle-Ottawa scoring guide that was adapted for this review. The study quality tool has possible scores from 0 to 5 and classifies studies as having low risk of bias (≥3 points) or high risk of bias (<3 points). The questions include: [1) Were participants recruited from multiple locations? 2) Was the sample size equal or greater than 200 participants? 3) Did all participants answer the question on PrEP uptake? 4) Was the PrEP uptake validated by such as medical record? 5) Does the study report descriptive statistics with proper measure of dispersion?]

dOnly data for 2004, 2008 and 2011 were used for this review. Data for 2014 were duplicates of another study (Hoots, 2016)

eOnly data for baseline of this cohort study were included in this review.

f2014 data on Adams (non-Southern US), Klevens (black, Latino, youth), Levy (South), Patrick (South), and Snowden (black, Latino, Youth, non-Southern US) are used as a subgroup of Hoots (2016) study. Overall prevalence was not included in this review.

gRaifman (black, Latino, youth) is used as a subgroup study of Chan (2015). Overall prevalence was not included in this review.

hChen (2015) reported data from 2004, 2008, 2011, 2014, and 2017. The previously published study (Chen, 2016) included 2004-2011 data. 2014 data were included a part of Hoots (2016). Thus, only 2017 data were included in this review.

iData from *One Thousand Strong* cohort were omitted from this review due to the possible duplication of data reported in Whitfield (2018).

Supplemental Table 2: Heterogeneity\* by study year and key population subgroups in US study participants

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | OverallI2 (k) | 2004-2012I2 (k) | 2013, 2014I2 (k) | 2015-2017I2 (k) |
| Overall | 97.05% (95) | 89.74% (22) | 88.03% (27) | 95.75% (46) |
|  MSM | 97.21% (80) | 90.04% (21) | 89.44% (20) | 96.43 (39) |
|  Black | 88.1% (40) | 13.27% (8) | 75.77% (14) | 76.61% (18) |
|  Hispanic/Latino | 93.1% (26) | 0% (6) | 8.70% (8) | 95.65% (12) |
|  PWID | 74.66% (5) | - | 59.95% (2) | 72.91% (3) |
|  Youth | 90.8% (19) | 0% (5) | 0% (6) | 92.24% (8) |
|  Southern US | 93.28% (19) | 88.76% (3) | 77.44% (8) | 94.32% (8) |
|  Transgender women | 63.24% (9) | - | 0% (4) | 72.99% (5) |
| Non-MSM | 79.81% (20) | (1) | 73.88% (8) | 73.10% (11) |
|  Black | 69.92% (5) | (1) | 0% (2) | 78.82% (2) |
|  Hispanic/Latino | 9.08% (4) | - | 0% (2) | 30.31% (2) |
|  PWID | 31.31% (3) | - | (1) | 0% (2) |
|  Youth | 44.14% (3) | - | (1) | 30.70% (2) |
|  Southern US | 61.09% (3) | - | 35.85% (2) | (1) |

MSM: men who have sex with men, Southern US: people in the Southern United States, PWID: persons who inject drugs

No study (-), I2: heterogeneity, k: number of surveys

\*Heterogeneity greater than or equal to 75% is considered high

Supplemental Table 3: Fixed effects pooled proportion of PrEP uptake by recall period in US study participants overall and in MSM and non-MSM participants

|  |  |  |  |
| --- | --- | --- | --- |
| Recall period | Overall | MSM | Non-MSM |
| k | % (95% CI) | k | % (95% CI) | k | % (95% CI) |
| Ever | 62 | 11.4 (11.1-11.7) | 48 | 11.5 (11.2-11.8) | 14 | 8.1 (6.9-9.4) |
| Current | 26 | 10.3 (10.0-10.6) | 25 | 10.3 (10.0-10.6) | 1 | 4.8 (2.4-9.2) |
| Past 6 months | 6 | 8.8 (8.1-9.5) | 6 | 8.8 (8.1-9.5) | 0 | - |
| Past 12 months | 10 | 7.9 (7.3-8.5) | 8 | 7.9 (7.4-8.5) | 2 | 0.5 (0.1-2.4) |
| Overall | 104 | 10.6 (10.4-10.8) | 87 | 10.6 (10.5-10.8) | 17 | 7.6 (6.5-18.9) |

MSM: men who have sex with men, k: number of surveys

Appendix III. List of Included Studies (N=95)

1. Chen YH, Snowden JM, McFarland W, Raymond HF. Pre-exposure prophylaxis (PrEP) use, seroadaptation, and sexual behavior among men who have sex with men, San Francisco, 2004-2014. *AIDS Behav* 2016; **20**(12): 2791-7.

2. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2006; **43**(3): 376-7.

3. Voetsch AC, Heffelfinger JD, Begley EB, Jafa-Bhushan K, Sullivan PS. Knowledge and Use of Preexposure and Postexposure Prophylaxis Among Attendees of Minority Gay Pride Events, 2005 Through 2006. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2007; **46**(3): 378-80.

4. Koblin BA, Mansergh G, Frye V, et al. Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2011; **58**(3): 319-27.

5. Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA, Hudson SM. Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted hiv infection among US men who have sex with men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2010; **55**(2): e14-e6.

6. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure Prophylaxis and Predicted Condom Use Among High-Risk Men Who Have Sex With Men. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2010; **54**(5): 548-55.

7. Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. *AIDS Patient Care STDS* 2010; **24**(11): 689-91.

8. Hood JE, Buskin SE, Dombrowski JC, et al. Dramatic increase in preexposure prophylaxis use among MSM in King County, Washington. *AIDS* 2015; **30**(3): 515-9.

9. Vermund SH, Krakower DS, Mimiaga MJ, et al. Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. *PLoS One* 2012; **7**(3): e33119.

10. Dolezal C, Frasca T, Giguere R, et al. Awareness of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) is low but interest is high among men engaging in condomless anal sex with men in Boston, Pittsburgh, and San Juan. *AIDS Educ Prev* 2015; **27**(4): 289-97.

11. Fallon SA, Park JN, Ogbue CP, Flynn C, German D. Awareness and acceptability of pre-exposure HIV prophylaxis among men who have sex with men in Baltimore. *AIDS Behav* 2017; **21**(5): 1268-77.

12. Patrick R, Forrest D, Cardenas G, et al. Awareness, willingness, and use of pre-exposure prophylaxis among men who have sex with men in Washington, DC and Miami-Dade county, FL: National HIV Behavioral Surveillance, 2011 and 2014. *J Acquir Immune Defic Syndr* 2017; **75 Suppl 3**: S375-S82.

13. Rucinski KB, Mensah NP, Sepkowitz KA, Cutler BH, Sweeney MM, Myers JE. Knowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York City. *AIDS Behav* 2013; **17**(6): 2180-4.

14. Newman CE, Saberi P, Gamarel KE, et al. Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: A mixed methods study. *PLoS One* 2012; **7**(11): e50061.

15. Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single young men who have sex with men. *Curr HIV Res* 2013; **11**(7): 520-7.

16. Brooks RA, Landovitz RJ, Regan R, Lee SJ, Allen VC, Jr. Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. *Int J STD AIDS* 2015; **26**(14): 1040-8.

17. Hoff CC, Chakravarty D, Bircher AE, et al. Attitudes towards PrEP and anticipated condom use among concordant HIV-negative and HIV-discordant male couples. *AIDS Patient Care STDS* 2015; **29**(7): 408-17.

18. Mimiaga MJ, Closson EF, Kothary V, Mitty JA. Sexual partnerships and considerations for HIV antiretroviral pre-exposure prophylaxis utilization among high-risk substance using men who have sex with men. *Arch Sex Behav* 2013; **43**(1): 99-106.

19. Chan PA, Rose J, Maher J, et al. A latent class analysis of risk factors for acquiring HIV among men who have sex with men: Implications for implementing pre-exposure prophylaxis programs. *AIDS Patient Care STDS* 2015; **29**(11): 597-605.

20. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. *J Acquir Immune Defic Syndr* 2015; **68**(4): 439-48.

21. Eaton LA, Driffin DD, Bauermeister J, Smith H, Conway-Washington C. Minimal awareness and stalled uptake of pre-exposure prophylaxis (PrEP) among at risk, HIV-negative, black men who have sex with men. *AIDS Patient Care STDS* 2015; **29**(8): 423-9.

22. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. *AIDS Care* 2017; **30**(1): 9-17.

23. Giguere R, Frasca T, Dolezal C, et al. Acceptability of three novel HIV prevention methods among young male and transgender female sex workers in Puerto Rico. *AIDS Behav* 2016; **20**(10): 2192-202.

24. Golub SA, Gamarel KE, Surace A. Demographic differences in PrEP-related stereotypes: Implications for implementation. *AIDS Behav* 2015; **21**(5): 1229-35.

25. Gupta S, Lounsbury DW, Patel VV. Low awareness and use of preexposure prophylaxis in a diverse online sample of men who have sex with men in New York City. *J Assoc Nurses AIDS Care* 2017; **28**(1): 27-33.

26. Khanna AS, Michaels S, Skaathun B, et al. Preexposure Prophylaxis Awareness and Use in a Population-Based Sample of Young Black Men Who Have Sex With Men. *JAMA Internal Medicine* 2016; **176**(1): 136-8.

27. Lancki N, Almirol E, Alon L, McNulty M, Schneider JA. PrEP guidelines have low sensitivity for identifying seroconverters in a sample of young black men who have sex with men in Chicago. *AIDS* 2017; **32**(3): 383-92.

28. Mayer KH, Oldenburg CE, Novak DS, Elsesser SA, Krakower DS, Mimiaga MJ. Early adopters: Correlates of HIV chemoprophylaxis use in recent online samples of US men who have sex with men. *AIDS Behav* 2015; **20**(7): 1489-98.

29. Oldenburg CE, Mitty JA, Biello KB, et al. Differences in attitudes about HIV pre-exposure prophylaxis use among stimulant versus alcohol using men who have sex with men. *AIDS Behav* 2015; **20**(7): 1451-60.

30. Raifman J, Nunn A, Oldenburg CE, et al. An evaluation of a clinical pre-exposure prophylaxis education intervention among men who have sex with men. *Health Serv Res* 2018; **53**(4): 2249-67.

31. Adams JW, Shinefeld J, Brady KA. Acceptability of oral preexposure prophylaxis among men who have sex with men in philadelphia. *J Acquir Immune Defic Syndr* 2016; **73**(3): e62-e5.

32. Eaton LA, Matthews DD, Driffin DD, Bukowski L, Wilson PA, Stall RD. A multi-US city assessment of awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among black men and transgender women who have sex with men. *Prevention Science* 2017; **18**(5): 505-16.

33. Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men—20 US cities, 2014. *Clin Infect Dis* 2016; **63**(5): 672-7.

34. Klevens RM, Martin BM, Doherty R, Fukuda HD, Cranston K, DeMaria A. Factors Associated with Pre-exposure Prophylaxis in a Highly Insured Population of Urban Men Who Have Sex with Men, 2014. *AIDS Behav* 2017; **22**(4): 1201-8.

35. Kurtz SP, Buttram ME. Misunderstanding of Pre-Exposure Prophylaxis Use Among Men Who Have Sex with Men: Public Health and Policy Implications. *LGBT Health* 2016; **3**(6): 461-4.

36. Colby DJ, Levy ME, Patrick R, et al. Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis. *PLoS One* 2017; **12**(8): e0183521.

37. Marks SJ, Merchant RC, Clark MA, et al. Potential healthcare Insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. *AIDS Patient Care STDS* 2017; **31**(11): 470-8.

38. Merchant RC, Corner D, Garza E, et al. Preferences for HIV pre-exposure prophylaxis (PrEP) information among men who have sex with men (MSM) at community outreach settings. *Journal of Gay & Lesbian Mental Health* 2015; **20**(1): 21-33.

39. Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. *AIDS Behav* 2016; **20**(7): 1390-9.

40. Snowden JM, Chen Y-H, McFarland W, Raymond HF. Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities. *Sex Transm Infect* 2017; **93**(1): 52-5.

41. Strauss BB, Greene GJ, Phillips G, et al. Exploring patterns of awareness and use of HIV pre-exposure prophylaxis among young men who have sex with men. *AIDS Behav* 2016; **21**(5): 1288-98.

42. Arrington-Sanders R, Morgan A, Oidtman J, Qian I, Celentano D, Beyrer C. A medical care missed opportunity: Preexposure prophylaxis and young black men who have sex with men. *J Adolesc Health* 2016; **59**(6): 725-8.

43. Beymer MR, Gildner JL, Holloway IW, Landovitz RJ. Acceptability of injectable and on-demand pre-exposure prophylaxis among an online sample of young men who have sex with men in California. *LGBT Health* 2018; **5**(6): 341-9.

44. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. *AIDS Behav* 2017; **21**(5): 1236-46.

45. Friedman MR, Sang JM, Bukowski LA, et al. Prevalence and correlates of PrEP awareness and use among black men who have sex with men and women (MSMW) in the United States. *AIDS Behav* 2019; 10.1007/s10461-019-02446-3.

46. Goedel WC, Halkitis PN, Greene RE, Hickson DA, Duncan DT. HIV risk behaviors, perceptions, and testing and preexposure prophylaxis (PrEP) awareness/use in Grindr-using men who have sex with men in Atlanta, Georgia. *J Assoc Nurses AIDS Care* 2016; **27**(2): 133-42.

47. Grov C, Rendina HJ, Jimenez R, Parsons JT. Using online settings to identify gay and bisexual men willing to take or with experience taking PrEP: Implications for researchers and providers. *AIDS Educ Prev* 2016; **28**(5): 378-92.

48. Holloway IW, Dougherty R, Gildner J, et al. Brief Report. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2017; **74**(1): 15-20.

49. Jaiswal J, Griffin M, Singer SN, et al. Structural barriers to pre-exposure prophylaxis use among young sexual minority men: The P18 cohort study. *Current HIV Research* 2018; **16**(3): 237-49.

50. Kahle EM, Sullivan S, Stephenson R. Functional knowledge of pre-exposure prophylaxis for HIV prevention among participants in a web-based survey of sexually active gay, bisexual, and other men who have sex with men: Cross-sectional study. *JMIR Public Health and Surveillance* 2018; **4**(1): e13.

51. Kalichman SC, Eaton L. Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men. *J Int AIDS Soc* 2017; **20**(1): 21534.

52. Kuhns LM, Hotton AL, Schneider J, Garofalo R, Fujimoto K. Use of pre-exposure prophylaxis (PrEP) in young men who have sex with men is associated with race, sexual risk behavior and peer network size. *AIDS Behav* 2017; **21**(5): 1376-82.

53. Li J, Berg CJ, Kramer MR, Haardörfer R, Zlotorzynska M, Sanchez TH. An integrated examination of county- and individual-level factors in relation to HIV pre-exposure prophylaxis awareness, willingness to use, and uptake among men who have sex with men in the US. *AIDS Behav* 2018; **23**(7): 1721-36.

54. Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2017; **74**(3): 285-92.

55. Patel RR, Luke DA, Proctor EK, et al. Sex venue-based network analysis to identify HIV prevention dissemination targets for men who have sex with men. *LGBT Health* 2018; **5**(1): 78-85.

56. Madiba S, Patel RR, Crane JS, et al. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. *PLoS One* 2018; **13**(12): e0209484-e.

57. Pawson M, Grov C. 'It's just an excuse to slut around': gay and bisexual mens' constructions of HIV pre-exposure prophylaxis (PrEP) as a social problem. *Sociol Health Illn* 2018; **40**(8): 1391-403.

58. Whitfield THF, John SA, Rendina HJ, Grov C, Parsons JT. Why I quit pre-exposure prophylaxis (PrEP)? A mixed-method study exploring reasons for PrEP discontinuation and potential re-initiation among gay and bisexual men. *AIDS Behav* 2018; **22**(11): 3566-75.

59. Biello KB, Mimiaga MJ, Santostefano CM, Novak DS, Mayer KH. MSM at highest risk for HIV acquisition express greatest interest and preference for injectable antiretroviral PrEP compared to daily, oral medication. *AIDS Behav* 2018; **22**(4): 1158-64.

60. Biello KB, Hosek S, Drucker MT, et al. Preferences for injectable PrEP among young U.S. cisgender men and transgender women and men who have sex with men. *Arch Sex Behav* 2017; **47**(7): 2101-7.

61. Clark JL, García M, Harris AL. PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. *PLoS One* 2017; **12**(9): e0184014.

62. Grov C, Jonathan Rendina H, Patel VV, Kelvin E, Anastos K, Parsons JT. Prevalence of and factors associated with the use of HIV serosorting and other biomedical prevention strategies among men who have sex with men in a US nationwide survey. *AIDS Behav* 2018; **22**(8): 2743-55.

63. Costa AB, Hammack PL, Meyer IH, Krueger EA, Lightfoot M, Frost DM. HIV testing and pre-exposure prophylaxis (PrEP) use, familiarity, and attitudes among gay and bisexual men in the United States: A national probability sample of three birth cohorts. *PLoS One* 2018; **13**(9): e0202806.

64. Hubach RD, Currin JM, Sanders CA, et al. Barriers to access and adoption of pre-exposure prophylaxis for the prevention of HIV among men who have sex with men (MSM) in a relatively rural state. *AIDS Educ Prev* 2017; **29**(4): 315-29.

65. Morgan E, Moran K, Ryan DT, Mustanski B, Newcomb ME. Threefold increase in PrEP uptake over time with high adherence among young men who have sex with men in Chicago. *AIDS Behav* 2018; **22**(11): 3637-44.

66. Newcomb ME, Moran K, Feinstein BA, Forscher E, Mustanski B. Pre-exposure prophylaxis (PrEP) use and condomless anal sex. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2018; **77**(4): 358-64.

67. Okafor CN, Gorbach PM, Ragsdale A, Quinn B, Shoptaw S. Correlates of preexposure prophylaxis (PrEP) use among men who have sex with men (MSM) in Los Angeles, California. *J Urban Health* 2017; **94**(5): 710-5.

68. Phillips G, Neray B, Birkett M, Felt D, Janulis P, Mustanski B. Role of social and sexual network factors in PrEP utilization among YMSM and transgender women in Chicago. *Prevention Science* 2019; 10.1007/s11121-019-00995-6.

69. Rolle CP, Rosenberg ES, Siegler AJ, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. *J Acquir Immune Defic Syndr* 2017; **76**(3): 250-8.

70. Sang JM, Matthews DD, Meanley SP, Eaton LA, Stall RD. Assessing HIV stigma on prevention strategies for black men who have sex with men in the United States. *AIDS Behav* 2018; **22**(12): 3879-86.

71. Shover CL, Javanbakht M, Shoptaw S, et al. HIV preexposure prophylaxis initiation at a large community clinic: Differences between eligibility, awareness, and uptake. *Am J Public Health* 2018; **108**(10): 1408-17.

72. Young LE, Schumm P, Alon L, et al. PrEP Chicago: A randomized controlled peer change agent intervention to promote the adoption of pre-exposure prophylaxis for HIV prevention among young Black men who have sex with men. *Clinical Trials* 2017; **15**(1): 44-52.

73. Brinkley-Rubinstein L, Peterson M, Arnold T, et al. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. *PLoS One* 2018; **13**(12): e0205593.

74. Chen YH, Guigayoma J, McFarland W, Snowden JM, Raymond HF. Increases in pre-exposure prophylaxis use and decreases in condom use: Behavioral patterns among HIV-negative San Francisco men who have sex with men, 2004-2017. *AIDS Behav* 2019; **23**(7): 1841-5.

75. Eaton LA, Matthews DD, Bukowski LA, et al. Elevated HIV prevalence and correlates of PrEP use among a community sample of black men who have sex with men. *J Acquir Immune Defic Syndr* 2018; **79**(3): 339-46.

76. John SA, Robles G, Starks TJ, Rendina HJ. Differences between groups of pre-exposure prophylaxis (PrEP) using couples in HIV-negative/unknown relationships. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2019; **81**(4): 419-28.

77. Meunier É, Siegel K. Sexual risk behaviors and perceptions of men who go to gay sex parties in New York City: Comparisons between three HIV groups. *The Journal of Sex Research* 2017; **55**(7): 880-91.

78. Quinn K, Dickson-Gomez J, Zarwell M, Pearson B, Lewis M. “A gay man and a doctor are just like, a recipe for destruction”: How racism and homonegativity in healthcare settings influence PrEP uptake among young black msm. *AIDS Behav* 2018; **23**(7): 1951-63.

79. Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. *Drug Alcohol Depend* 2016; **164**: 8-13.

80. Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women. *AIDS Behav* 2015; **20**(7): 1470-7.

81. Rodriguez VJ, Spence A, Monda M, Potter J, Jones D. Couples living with HIV. *Journal of the International Association of Providers of AIDS Care (JIAPAC)* 2016; **16**(2): 133-9.

82. Calabrese SK, Underhill K, Earnshaw VA, et al. Framing HIV pre-exposure prophylaxis (PrEP) for the general public: How inclusive messaging may prevent prejudice from diminishing public support. *AIDS Behav* 2016; **20**(7): 1499-513.

83. Patel AS, Goparaju L, Sales JM, et al. Brief Report. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2019; **80**(5): 527-32.

84. Raifman JR, Schwartz SR, Sosnowy CD, et al. Brief Report. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2019; **80**(1): 36-9.

85. Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. *Global Public Health* 2016; **11**(7-8): 1060-75.

86. Wilson E, Chen Y-H, Pomart WA, Arayasirikul S. Awareness, interest, and HIV pre-exposure prophylaxis candidacy among young transwomen. *AIDS Patient Care STDS* 2016; **30**(4): 147-50.

87. Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper GW. Characterizing the HIV prevention and care continua in a sample of transgender youth in the U.S. *AIDS Behav* 2017; **21**(12): 3312-27.

88. Schueler K, Ferreira M, Nikolopoulos G, et al. Pre-exposure prophylaxis (PrEP) awareness and use within high HIV transmission networks. *AIDS Behav* 2019; **23**(7): 1893-903.

89. Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. *Harm Reduction Journal* 2017; **14**(1): 40.

90. Misra K, Udeagu C-C. Disparities in awareness of HIV postexposure and preexposure prophylaxis among notified partners of HIV-positive individuals, New York City 2015–2017. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2017; **76**(2): 132-40.

91. Rael CT, Martinez M, Giguere R, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. *AIDS Behav* 2018; **22**(11): 3627-36.

92. Shrestha R, Karki P, Altice FL, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. *Drug Alcohol Depend* 2017; **173**: 107-16.

93. Bazzi AR, Biancarelli DL, Childs E, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. *AIDS Patient Care STDS* 2018; **32**(12): 529-37.

94. Chandran A, Marcell AV, Sanders RA, et al. Characteristics of the provider-patient encounter associated with awareness of and willingness to take PrEP among young minority urban males in Baltimore City. *AIDS Educ Prev* 2019; **31**(3): 237-45.

95. Willie TC, Stockman JK, Keene DE, Calabrese SK, Alexander KA, Kershaw TS. Social networks and its impact on womenʼs awareness, interest, and uptake of HIV pre-exposure prophylaxis (PrEP). *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2019; **80**(4): 386-93.